One challenge to HCV elimination through therapeutic intervention is reinfection. The aim of this analysis was to calculate the incidence of HCV reinfection among both HIV-positive and HIV-negative individuals treated for recent HCV infection (estimated infection duration <18 months). Individuals with recent HCV infection who achieved an end-of-treatment response in four open-label studies between 2004 and 2015 in Australia and New Zealand were assessed for HCV reinfection, confirmed by sequencing of the Core-E2 and/or NS5B regions. Reinfection incidence was calculated using person-time of observation. Exact Poisson regression analysis was used to assess factors associated with HCV reinfection. The cohort at risk for reinfection (n=120; 83%...
OBJECTIVES: Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected ...
Unsafe injecting practices put injecting drug users (IDUs) at repeat exposure to infection with the ...
Background and Aim: Despite that 60–90% of injection drug users (IDUs) are infected with hepatitis ...
One challenge to HCV elimination through therapeutic intervention is reinfection. The aim of this an...
OBJECTIVE Reinfection poses a challenge to HCV elimination. This analysis assessed incidence of, ...
Abstract Background The aim of this analysis was to calculate the incidence of hepatitis C virus (HC...
Infection with hepatitis C virus (HCV) does not induce protective immunity, and re-exposure to HCV c...
BACKGROUND & AIMS: Direct-acting antiviral therapies (DAA) are an important tool for hepatitis C...
BACKGROUND & AIMS: Direct-acting antiviral therapies (DAA) are an important tool for hepatitis C vir...
OBJECTIVE: Liver disease secondary to hepatitis C virus (HCV) infection in the context of HIV infect...
Background: People remain at risk of reinfection with hepatitis C virus (HCV), even after clearance ...
Injecting risk behaviours among people who inject drugs (PWID) and high-risk sexual practices among ...
Background: Human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) are at high ...
BACKGROUND: Human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) are at high ...
Objectives: Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected ...
OBJECTIVES: Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected ...
Unsafe injecting practices put injecting drug users (IDUs) at repeat exposure to infection with the ...
Background and Aim: Despite that 60–90% of injection drug users (IDUs) are infected with hepatitis ...
One challenge to HCV elimination through therapeutic intervention is reinfection. The aim of this an...
OBJECTIVE Reinfection poses a challenge to HCV elimination. This analysis assessed incidence of, ...
Abstract Background The aim of this analysis was to calculate the incidence of hepatitis C virus (HC...
Infection with hepatitis C virus (HCV) does not induce protective immunity, and re-exposure to HCV c...
BACKGROUND & AIMS: Direct-acting antiviral therapies (DAA) are an important tool for hepatitis C...
BACKGROUND & AIMS: Direct-acting antiviral therapies (DAA) are an important tool for hepatitis C vir...
OBJECTIVE: Liver disease secondary to hepatitis C virus (HCV) infection in the context of HIV infect...
Background: People remain at risk of reinfection with hepatitis C virus (HCV), even after clearance ...
Injecting risk behaviours among people who inject drugs (PWID) and high-risk sexual practices among ...
Background: Human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) are at high ...
BACKGROUND: Human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) are at high ...
Objectives: Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected ...
OBJECTIVES: Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected ...
Unsafe injecting practices put injecting drug users (IDUs) at repeat exposure to infection with the ...
Background and Aim: Despite that 60–90% of injection drug users (IDUs) are infected with hepatitis ...